NR 566 ADVANCED PHARMACOLOGY CARE OF THE FAMILY
MIDTERM QUIZ BANK 2026/2027 | Questions and Verified
Answers | Chamberlain College | Pass Guaranteed - A+
Graded
Pharmacokinetics, Pharmacodynamics & Prescribing Principles
Q1: A 58-year-old patient with liver cirrhosis is prescribed a medication that undergoes
extensive first-pass metabolism. Which effect is expected?
A. Increased bioavailability of the medication
B. Decreased bioavailability of the medication [CORRECT]
C. Enhanced renal excretion of the medication
D. Increased protein binding of the medication
Correct Answer: B
Rationale: Liver disease impairs first-pass metabolism, which normally reduces
bioavailability of orally administered drugs. This leads to higher-than-expected drug
levels. Renal excretion and protein binding are not directly affected by hepatic first-pass
metabolism.
Q2: A patient taking phenytoin for seizures is started on fluconazole for a fungal
infection. Which interaction is most concerning?
A. Phenytoin toxicity due to CYP2C9 inhibition by fluconazole [CORRECT]
B. Reduced antifungal efficacy due to phenytoin induction
C. Enhanced analgesic effects of phenytoin
D. Decreased seizure threshold from antifungal therapy
Correct Answer: A
Rationale: Fluconazole is a potent CYP2C9 inhibitor, and phenytoin is a CYP2C9
substrate. This interaction increases phenytoin levels significantly, risking toxicity.
Phenytoin is an enzyme inducer, not inhibitor, and doesn't affect fluconazole efficacy.
,Q3: Which factor most significantly affects the volume of distribution of a highly
lipophilic drug?
A. Degree of ionization at physiological pH
B. Extent of protein binding to albumin
C. Amount of adipose tissue in the body [CORRECT]
D. Rate of glomerular filtration
Correct Answer: C
Rationale: Lipophilic drugs distribute extensively into adipose tissue, increasing volume
of distribution. While protein binding and ionization affect distribution, adipose tissue
mass is the dominant factor for lipophilic drugs. GFR affects elimination, not
distribution.
Q4: A drug has a half-life of 6 hours. Approximately how long will it take to reach steady
state with daily dosing?
A. 6 hours
B. 12 hours
C. 30 hours (approximately 5 half-lives) [CORRECT]
D. 60 hours
Correct Answer: C
Rationale: Steady state is achieved after approximately 5 half-lives, regardless of dosing
interval. With a 6-hour half-life, this equals 30 hours. This principle applies to all drugs
following first-order kinetics.
Q5: A patient with renal failure has a drug that is 80% renally excreted unchanged. What
adjustment is most appropriate?
A. Increase the dose and lengthen the dosing interval
B. Decrease the dose or lengthen the dosing interval [CORRECT]
C. No adjustment needed for renally cleared drugs
D. Switch to the intravenous route exclusively
Correct Answer: B
,Rationale: For predominantly renally excreted drugs, renal impairment requires dose
reduction or interval prolongation to prevent accumulation and toxicity. Increasing the
dose would worsen toxicity, and route change doesn't address clearance issues.
Q6: Which drug is a prodrug requiring CYP2D6 metabolism to become active?
A. Lisinopril
B. Enalapril
C. Codeine [CORRECT]
D. Warfarin
Correct Answer: C
Rationale: Codeine is a prodrug converted by CYP2D6 to morphine (its active
metabolite). Poor metabolizers get inadequate analgesia; ultra-rapid metabolizers risk
toxicity. Lisinopril is active as given; enalapril is a prodrug but converted by esterases,
not CYP2D6.
Q7: A patient is taking warfarin and starts taking a CYP3A4 inducer. Which effect is
expected on warfarin therapy?
A. Increased INR and bleeding risk
B. Decreased INR and thrombosis risk [CORRECT]
C. No change in anticoagulation status
D. Enhanced protein binding and increased free warfarin
Correct Answer: B
Rationale: CYP3A4 inducers increase warfarin metabolism, decreasing its effect and
INR, potentially leading to thrombosis. Warfarin metabolism involves multiple CYP
enzymes, but 3A4 and 2C9 are most significant.
Q8: Which pharmacokinetic parameter determines the loading dose of a drug?
A. Clearance
B. Volume of distribution [CORRECT]
C. Half-life
D. Bioavailability
Correct Answer: B
, Rationale: Loading dose = (Target concentration × Volume of distribution) /
Bioavailability. Volume of distribution determines how much drug is needed to achieve
therapeutic concentration rapidly. Clearance and half-life determine maintenance
dosing.
Q9: A drug with a narrow therapeutic index requires which monitoring approach?
A. Therapeutic drug monitoring to maintain levels within safe range [CORRECT]
B. Routine liver function testing every 6 months
C. Peak and trough levels only for antibiotics
D. No special monitoring required
Correct Answer: A
Rationale: Narrow therapeutic index drugs (digoxin, lithium, phenytoin, warfarin) have
small safety margins between efficacy and toxicity, requiring therapeutic drug
monitoring. While organ function monitoring may be needed, drug level monitoring is
essential.
Q10: Which statement about receptor agonists is accurate?
A. Full agonists have higher efficacy than partial agonists at the same receptor
[CORRECT]
B. Partial agonists have no intrinsic activity
C. Competitive antagonists irreversibly bind receptors
D. Inverse agonists increase baseline receptor activity
Correct Answer: A
Rationale: Full agonists produce maximal response; partial agonists produce
submaximal response even at 100% receptor occupancy. Competitive antagonists are
reversible; inverse agonists decrease baseline activity (stabilize inactive receptor state).
Q11: A patient is prescribed a medication that is a substrate of P-glycoprotein. Which
food/herb significantly affects its absorption?
A. Grapefruit juice (CYP3A4 inhibition)
B. St. John's wort (P-gp induction) [CORRECT]
C. High-fat meals (enhanced lipophilic absorption)
D. Dairy products (calcium chelation)
MIDTERM QUIZ BANK 2026/2027 | Questions and Verified
Answers | Chamberlain College | Pass Guaranteed - A+
Graded
Pharmacokinetics, Pharmacodynamics & Prescribing Principles
Q1: A 58-year-old patient with liver cirrhosis is prescribed a medication that undergoes
extensive first-pass metabolism. Which effect is expected?
A. Increased bioavailability of the medication
B. Decreased bioavailability of the medication [CORRECT]
C. Enhanced renal excretion of the medication
D. Increased protein binding of the medication
Correct Answer: B
Rationale: Liver disease impairs first-pass metabolism, which normally reduces
bioavailability of orally administered drugs. This leads to higher-than-expected drug
levels. Renal excretion and protein binding are not directly affected by hepatic first-pass
metabolism.
Q2: A patient taking phenytoin for seizures is started on fluconazole for a fungal
infection. Which interaction is most concerning?
A. Phenytoin toxicity due to CYP2C9 inhibition by fluconazole [CORRECT]
B. Reduced antifungal efficacy due to phenytoin induction
C. Enhanced analgesic effects of phenytoin
D. Decreased seizure threshold from antifungal therapy
Correct Answer: A
Rationale: Fluconazole is a potent CYP2C9 inhibitor, and phenytoin is a CYP2C9
substrate. This interaction increases phenytoin levels significantly, risking toxicity.
Phenytoin is an enzyme inducer, not inhibitor, and doesn't affect fluconazole efficacy.
,Q3: Which factor most significantly affects the volume of distribution of a highly
lipophilic drug?
A. Degree of ionization at physiological pH
B. Extent of protein binding to albumin
C. Amount of adipose tissue in the body [CORRECT]
D. Rate of glomerular filtration
Correct Answer: C
Rationale: Lipophilic drugs distribute extensively into adipose tissue, increasing volume
of distribution. While protein binding and ionization affect distribution, adipose tissue
mass is the dominant factor for lipophilic drugs. GFR affects elimination, not
distribution.
Q4: A drug has a half-life of 6 hours. Approximately how long will it take to reach steady
state with daily dosing?
A. 6 hours
B. 12 hours
C. 30 hours (approximately 5 half-lives) [CORRECT]
D. 60 hours
Correct Answer: C
Rationale: Steady state is achieved after approximately 5 half-lives, regardless of dosing
interval. With a 6-hour half-life, this equals 30 hours. This principle applies to all drugs
following first-order kinetics.
Q5: A patient with renal failure has a drug that is 80% renally excreted unchanged. What
adjustment is most appropriate?
A. Increase the dose and lengthen the dosing interval
B. Decrease the dose or lengthen the dosing interval [CORRECT]
C. No adjustment needed for renally cleared drugs
D. Switch to the intravenous route exclusively
Correct Answer: B
,Rationale: For predominantly renally excreted drugs, renal impairment requires dose
reduction or interval prolongation to prevent accumulation and toxicity. Increasing the
dose would worsen toxicity, and route change doesn't address clearance issues.
Q6: Which drug is a prodrug requiring CYP2D6 metabolism to become active?
A. Lisinopril
B. Enalapril
C. Codeine [CORRECT]
D. Warfarin
Correct Answer: C
Rationale: Codeine is a prodrug converted by CYP2D6 to morphine (its active
metabolite). Poor metabolizers get inadequate analgesia; ultra-rapid metabolizers risk
toxicity. Lisinopril is active as given; enalapril is a prodrug but converted by esterases,
not CYP2D6.
Q7: A patient is taking warfarin and starts taking a CYP3A4 inducer. Which effect is
expected on warfarin therapy?
A. Increased INR and bleeding risk
B. Decreased INR and thrombosis risk [CORRECT]
C. No change in anticoagulation status
D. Enhanced protein binding and increased free warfarin
Correct Answer: B
Rationale: CYP3A4 inducers increase warfarin metabolism, decreasing its effect and
INR, potentially leading to thrombosis. Warfarin metabolism involves multiple CYP
enzymes, but 3A4 and 2C9 are most significant.
Q8: Which pharmacokinetic parameter determines the loading dose of a drug?
A. Clearance
B. Volume of distribution [CORRECT]
C. Half-life
D. Bioavailability
Correct Answer: B
, Rationale: Loading dose = (Target concentration × Volume of distribution) /
Bioavailability. Volume of distribution determines how much drug is needed to achieve
therapeutic concentration rapidly. Clearance and half-life determine maintenance
dosing.
Q9: A drug with a narrow therapeutic index requires which monitoring approach?
A. Therapeutic drug monitoring to maintain levels within safe range [CORRECT]
B. Routine liver function testing every 6 months
C. Peak and trough levels only for antibiotics
D. No special monitoring required
Correct Answer: A
Rationale: Narrow therapeutic index drugs (digoxin, lithium, phenytoin, warfarin) have
small safety margins between efficacy and toxicity, requiring therapeutic drug
monitoring. While organ function monitoring may be needed, drug level monitoring is
essential.
Q10: Which statement about receptor agonists is accurate?
A. Full agonists have higher efficacy than partial agonists at the same receptor
[CORRECT]
B. Partial agonists have no intrinsic activity
C. Competitive antagonists irreversibly bind receptors
D. Inverse agonists increase baseline receptor activity
Correct Answer: A
Rationale: Full agonists produce maximal response; partial agonists produce
submaximal response even at 100% receptor occupancy. Competitive antagonists are
reversible; inverse agonists decrease baseline activity (stabilize inactive receptor state).
Q11: A patient is prescribed a medication that is a substrate of P-glycoprotein. Which
food/herb significantly affects its absorption?
A. Grapefruit juice (CYP3A4 inhibition)
B. St. John's wort (P-gp induction) [CORRECT]
C. High-fat meals (enhanced lipophilic absorption)
D. Dairy products (calcium chelation)
